- Home
- COLL vs PHAR Comparison
COLL vs PHAR Comparison
Compare COLL & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COLL
- PHAR
- Stock Information
- Founded
- COLL 2002
- PHAR 1988
- Country
- COLL United States
- PHAR Netherlands
- Employees
- COLL N/A
- PHAR N/A
- Industry
- COLL Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- COLL Health Care
- PHAR Health Care
- Exchange
- COLL Nasdaq
- PHAR Nasdaq
- Market Cap
- COLL 1.1B
- PHAR 951.7M
- IPO Year
- COLL 2015
- PHAR N/A
- Fundamental
- Price
- COLL $45.49
- PHAR $16.96
- Analyst Decision
- COLL Strong Buy
- PHAR Strong Buy
- Analyst Count
- COLL 5
- PHAR 3
- Target Price
- COLL $45.40
- PHAR $30.00
- AVG Volume (30 Days)
- COLL 520.4K
- PHAR 17.7K
- Earning Date
- COLL 11-06-2025
- PHAR 11-06-2025
- Dividend Yield
- COLL N/A
- PHAR N/A
- EPS Growth
- COLL N/A
- PHAR N/A
- EPS
- COLL 1.63
- PHAR 0.00
- Revenue
- COLL $757,067,000.00
- PHAR $362,274,000.00
- Revenue This Year
- COLL $21.41
- PHAR $17.70
- Revenue Next Year
- COLL $3.28
- PHAR $12.25
- P/E Ratio
- COLL $28.29
- PHAR $2,895.69
- Revenue Growth
- COLL 26.34
- PHAR 26.78
- 52 Week Low
- COLL $23.23
- PHAR $7.31
- 52 Week High
- COLL $48.18
- PHAR $17.76
- Technical
- Relative Strength Index (RSI)
- COLL 74.50
- PHAR 58.13
- Support Level
- COLL $35.26
- PHAR $15.79
- Resistance Level
- COLL $48.18
- PHAR $17.67
- Average True Range (ATR)
- COLL 1.74
- PHAR 0.78
- MACD
- COLL 0.93
- PHAR 0.35
- Stochastic Oscillator
- COLL 80.20
- PHAR 75.39
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.